Blog
RSS FeedPosted by Michael Wonder on 23 Nov 2022
ICER to assess gene therapies for sickle cell disease
23 November 2022 - Report will be subject of CTAF meeting in June 2023; draft scoping document open to public ...
Posted by Michael Wonder on 02 Nov 2022
ICER publishes evidence report on gene therapies for haemophilia A and B
2 November 2022 - Duration of benefit with gene therapies and risks for rare side effects remain major uncertainties. ...
Posted by Michael Wonder on 13 Sep 2022
ICER releases draft evidence report on gene therapies for haemophilia A and B
13 September 2022 - Registration now open for 20 September “Early Insights” webinar. ...
Posted by Michael Wonder on 19 Jul 2022
ICER publishes final evidence report and policy recommendations on beti-cel gene therapy for beta thalassaemia
19 July 2022 - Independent appraisal committee unanimously determined that evidence is adequate to demonstrate that beti-cel provides a net ...
Posted by Michael Wonder on 02 Jun 2022
ICER publishes evidence report on gene therapy for beta thalassaemia
2 June 2022 - Evidence judged to demonstrate that beti-cel provides net health benefit to patients with transfusion-dependent thalassaemia. ...
Posted by Michael Wonder on 05 May 2022
ICER to assess gene therapies for haemophilia A and B
5 May 2022 - Report will be subject of CTAF meeting in November 2022; draft scoping document open to public ...
Posted by Michael Wonder on 05 May 2022
ICER’s favourable assessment of Bluebird Bio’s gene therapy Zynteglo may have important pricing and reimbursement implications
5 May 2022 - ICER evaluated the clinical and cost-effectiveness - as well as budgetary impact - of one of two ...
Posted by Michael Wonder on 13 Apr 2022
ICER releases draft evidence report on gene therapy for beta thalassaemia
13 April 2022 - Public comment period now open until 10 May 2022; requests to make oral comment during public ...
Posted by Michael Wonder on 24 Nov 2021
ICER to assess gene therapy for beta thalassaemia
24 November 2021 - Report will be subject of New England CEPAC meeting in June 2022; draft scoping document open ...
Posted by Michael Wonder on 18 Jan 2021
ICER issues correction to final evidence report on new therapies for bladder cancer
15 January 2021 - After correcting an input to the cost-effectiveness model, ICER’s health-benchmark price benchmark range for nadofaragene firadenovec has ...
Posted by Michael Wonder on 03 Mar 2020
ICER to postpone assessment of gene therapy for beta thalassemia
3 March 2020 - Due to delay in regulatory submission, ICER will reinitiate assessment at a future date — ...
Posted by Michael Wonder on 25 Jan 2020
ICER posts draft scoping document for the assessment of treatments for haemophilia A
24 January 2020 - Document open to public comment until 13 February 2020. ...
Posted by Michael Wonder on 06 Jan 2020
ICER posts draft scoping document for the assessment of treatments for beta thalassaemia
6 January 2020 - Document open to public comment until 27 January 2020. ...
Posted by Michael Wonder on 04 Jan 2020
ICER to assess gene therapy for haemophilia A
3 January 2020 - Report will be subject of New England CEPAC meeting in August 2020; open Input now being accepted ...
Posted by Michael Wonder on 07 Aug 2019
ICER issues statement regarding manufacturer's manipulation of data from animal testing of Zolgensma
7 August 2019 - Yesterday afternoon, the FDA announced that Novartis informed the agency in June of a data manipulation ...